The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC).
S. M. Gadgeel
Consultant or Advisory Role - AstraZeneca; Lilly
Honoraria - Lilly
J. C. Ruckdeschel
No relevant relationships to disclose
A. J. Wozniak
Consultant or Advisory Role - AstraZeneca; Lilly
Honoraria - Lilly
W. Chen
No relevant relationships to disclose
D. Hackstock
No relevant relationships to disclose
C. Galasso
No relevant relationships to disclose
A. Burger
No relevant relationships to disclose
S. P. Ivy
No relevant relationships to disclose
P. LoRusso
Consultant or Advisory Role - AstraZeneca (U)
M. J. Edelman
Consultant or Advisory Role - Lilly